This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Malignant neoplasm of other endocrine glands and related structures, including Hilmo
C3_ENDOCRINE_NAS_WIDE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
170 |
4. Check minimum number of eventsNone |
170 |
5. Include endpointsNone |
170 |
6. Filter based on genotype QC (FinnGen only) |
164 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Malignant neoplasm of other endocrine glands and related structures, including Hilmo
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 164 | 94 | 70 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 56.63 | 50.33 | 65.09 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 170
- Matched controls
- 1700
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
130
Kela drug reimbursment
Malignant tumour
+∞
50.6
46
*
C75.0
ICD-10 Finland
Malignant neoplasm: Parathyroid gland
+∞
49.4
45
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
16.6
45.2
42
33
H02AB02
ATC
dexamethasone; systemic
85.1
45.1
49
8
JN4BD
NOMESCO Finland
Extensive body CT
11.8
29.5
33
34
C75.9
ICD-10 Finland
Malignant neoplasm: Endocrine gland, unspecified
+∞
29.0
27
*
A03FA01
ATC
metoclopramide; systemic, rectal
6.8
28.7
57
117
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
24.6
23
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
24.6
23
*
H03AA01
ATC
levothyroxine sodium; systemic
5.0
24.0
79
250
A04AA02
ATC
granisetron; systemic, transdermal
+∞
23.5
22
*
8010/3-C75.0
ICD-O-3
Carcinoma, NOS, of parathyroid gland
+∞
23.5
22
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
138.8
23.2
24
*
XX3DW
NOMESCO Finland
Time consuming IT work
9.1
22.4
30
39
C75.3
ICD-10 Finland
Malignant neoplasm: Pineal gland
+∞
22.4
21
*
H02AB09
ATC
hydrocortisone; systemic
27.6
20.8
28
12
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
33.7
20.3
26
9
WZC00
NOMESCO Finland
Treatment plan or consultation
4.4
20.2
81
292
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
+∞
19.1
18
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
19.1
18
*
8260/3-C73.9
ICD-O-3
Papillary adenocarcinoma, NOS, of thyroid gland
+∞
18.0
17
*
WX408
NOMESCO Finland
General anesthesy, balanced
4.2
17.5
67
230
N02AA05
ATC
oxycodone; systemic
4.9
17.4
47
123
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
17.0
16
*
E23.00
ICD-10 Finland
Panhypopituitarism
187.6
16.8
17
*
A04AA01
ATC
ondansetron; systemic, rectal
18.1
16.3
25
16
C75.1
ICD-10 Finland
Malignant neoplasm: Pituitary gland
+∞
15.9
15
*
JN4AD
NOMESCO Finland
Body CT examination
7.9
15.7
23
33
ZXE10
NOMESCO Finland
More than one and less than three hours
3.7
15.6
85
365
BAA40
NOMESCO Finland
Unilateral lobectomy of thyroid gland
26.4
15.5
21
9
115
Kela drug reimbursment
Breast cancer
+∞
14.8
14
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
39.9
14.8
18
5
BBA40
NOMESCO Finland
Subtotal parathyroidectomy
58.4
14.1
16
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
13.7
13
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
13.7
13
*
8680/3-C75.5
ICD-O-3
Paraganglioma, NOS, of aortic body and other paraganglia
+∞
13.7
13
*
L03AA13
ATC
pegfilgrastim; parenteral
151.6
13.7
14
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
151.6
13.7
14
*
WZC30
NOMESCO Finland
Teaching
4.3
12.9
39
110
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
22.1
12.8
18
9
Z51.5
ICD-10 Finland
Palliative care
13.1
12.7
22
19
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
29.2
12.3
16
6
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.4
12.1
26
55
E83.50
ICD-10 Finland
Hypercalcemia
32.7
11.9
15
5
101
Kela drug reimbursment
Anterior pituitary hypofunction
32.7
11.9
15
5
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.7
11.7
46
156
C73
ICD-10 Finland
Malignant neoplasm of thyroid gland
+∞
11.6
11
*
C75.8
ICD-10 Finland
Malignant neoplasm: Pluriglandular involvement, unspecified
+∞
11.6
11
*
104
Kela drug reimbursment
Thyroid insufficiency
5.0
11.5
27
62
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.0
11.3
37
110
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
17.0
11.1
17
11
M05BX04
ATC
denosumab; parenteral
5.6
10.9
22
44
PJA12
NOMESCO Finland
Sentinel node biopsy
116.9
10.5
11
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
116.9
10.5
11
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
10.5
10
*
116
Kela drug reimbursment
Prostate cancer
+∞
10.5
10
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
10.5
10
*
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
34.9
10.5
13
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.9
10.5
72
339
ZX120
NOMESCO Finland
Intravenous
4.9
10.5
25
58
WF002
NOMESCO Finland
Radical radiotherapy
42.8
10.1
12
*
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
18.9
9.6
14
8
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
+∞
9.5
9
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
9.5
9
*
ZXD10
NOMESCO Finland
Scheduled procedure
2.7
9.1
78
406
ZXE20
NOMESCO Finland
More than three and less than five hours
3.6
9.0
34
111
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
10.9
8.7
16
16
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
29.2
8.6
11
*
L03AA02
ATC
filgrastim; parenteral
94.6
8.5
9
*
L01BC06
ATC
capecitabine; oral
+∞
8.4
8
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
8.4
8
*
C75.2
ICD-10 Finland
Malignant neoplasm: Craniopharyngeal duct
+∞
8.4
8
*
D35.59
ICD-10 Finland
Other paragangliom
+∞
8.4
8
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
8.4
8
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
8.4
8
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
8.4
8
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
7.9
8.2
18
25
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
18.3
8.2
12
7
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.9
8.0
13
10
L02BG04
ATC
letrozole; oral
16.0
7.8
12
8
ZXE00
NOMESCO Finland
One hour or less
2.5
7.8
79
438
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
7.7
60
294
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
26.4
7.7
10
*
D44.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Thyroid gland
26.4
7.7
10
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
14.2
7.5
12
9
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
+∞
7.3
7
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
7.3
7
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
7.3
7
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
7.3
7
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
7.3
7
*
E23.2
ICD-10 Finland
Diabetes insipidus
+∞
7.3
7
*
R50.9
ICD-10 Finland
Fever, unspecified
3.1
7.3
35
132
Z31.5
ICD-10 Finland
Genetic counselling
6.2
7.0
18
32
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
41.8
6.8
8
*
321
Kela drug reimbursment
Paricalcitol and cinacalcet
41.8
6.8
8
*
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
41.8
6.8
8
*
L02BA01
ATC
tamoxifen; oral
41.8
6.8
8
*
WX402
NOMESCO Finland
General anaesthesia
2.8
6.7
38
157
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
7.9
6.6
14
19
D35.1
ICD-10 Finland
Benign neoplasm: Parathyroid gland
72.5
6.5
7
*
BBA20
NOMESCO Finland
Exploration of parathyroid gland
72.5
6.5
7
*
BB1BQ
NOMESCO Finland
Extensive scintigraphy of parathyroid gland, 2 isotopes, SPECT and low-dose CT
72.5
6.5
7
*
H05BX01
ATC
cinacalcet; oral
27.8
6.3
8
*
ZXC86
NOMESCO Finland
Use of endoscopic device
27.8
6.3
8
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
6.3
6
*
Y77
ICPC
Malignant neoplasm prostate
+∞
6.3
6
*
C71.99
ICD-10 Finland
Malignant tumor in unspecified localization in the brain other or unspecified histology
+∞
6.3
6
*
C73, C75,
ICD-10 Finland
+∞
6.3
6
*
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
+∞
6.3
6
*
C74.0
ICD-10 Finland
Malignant neoplasm: Cortex of adrenal gland
+∞
6.3
6
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
6.3
6
*
C74.1
ICD-10 Finland
Malignant neoplasm: Medulla of adrenal gland
+∞
6.3
6
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
D35.50
ICD-10 Finland
Carotid body
+∞
6.3
6
*
C75.5
ICD-10 Finland
Malignant neoplasm: Aortic body and other paraganglia
+∞
6.3
6
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
6.3
6
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
6.3
6
*
L02BG06
ATC
exemestane; oral
+∞
6.3
6
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
13.2
6.2
10
8
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
6.1
82
502
HA1AA
NOMESCO Finland
X-ray mammography
7.7
6.0
13
18
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
44
114
4.86
16.45
3.7
2.9
—
—
—
0
0
107
551
3.54
14.43
14.6
5.5
1.23
1.22
mmol/l
0.37
102
501
113
622
3.44
13.27
14.8
5.7
1.23
1.22
mmol/l
0.44
81
542
35
97
4.28
11.80
8.3
3.1
115.34
75.54
ng/l
0.92
29
84
22
59
4.13
7.63
9.1
6.2
24.74
25.09
mmol/l
0.19
22
59
14
16
9.42
7.20
1.3
1.1
—
—
—
0
0
22
69
3.51
6.12
8.0
9.7
96.05
93.27
%
2.74
22
69
107
1348
0.44
5.79
4.2
4.4
1.40
1.48
mmol/l
1.34
99
1250
96
637
2.16
5.70
10.8
3.7
14.57
11.31
umol/l
0.28
90
592
112
1383
0.44
5.59
4.6
4.9
2.63
2.70
mmol/l
0.42
102
1287
8
5
16.68
5.46
2.1
1.2
56.75
62.20
nmol/l
—
8
5
81
515
2.09
5.26
6.6
3.6
34.62
36.05
g/l
1.18
75
479
13
23
6.03
5.18
2.8
1.4
—
—
—
0
0
110
1358
0.46
5.16
4.2
4.4
4.50
4.58
mmol/l
0.37
102
1268
102
1293
0.47
5.16
3.8
4.0
1.45
1.24
mmol/l
2.06
93
1186
17
51
3.59
5.03
1.7
1.3
19.41
20.69
iu/l
0.05
12
43
87
577
2.04
4.95
13.1
15.3
1.24
1.33
inr
0.46
38
157
83
550
1.99
4.65
3.0
2.4
—
—
—
0
0
7
5
14.51
4.61
1.0
1.8
—
—
—
0
0
11
21
5.52
4.22
3.6
1.8
4.77
4.82
kpa
0.09
11
21
57
349
1.95
3.88
3.2
2.6
0.86
0.37
e6/l
0.44
50
241
45
264
1.96
3.42
2.8
2.0
—
—
—
0
0
67
449
1.81
3.37
3.5
2.8
—
—
—
0
0
27
133
2.22
3.23
6.7
10.8
0.70
1.45
mmol/l
0.39
21
111
80
574
1.74
3.14
3.3
2.2
74.74
76.98
nmol/l
0.34
73
507
8
16
5.19
3.09
3.0
4.2
63.88
62.25
%
—
8
16
123
1002
1.82
3.05
14.6
5.0
88.14
75.45
u/l
1.44
117
915
5
5
10.25
2.99
1.0
1.0
2.74
4.22
umol/l
—
5
5
94
713
1.71
2.97
18.3
5.9
4.32
4.24
e9/l
0.12
85
622
6
9
6.86
2.89
1.8
1.8
—
—
—
0
0
5
6
8.54
2.76
1.2
2.8
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
10
29
3.60
2.74
1.8
1.7
0.42
0.34
u/ml
—
5
15
9
26
3.60
2.52
1.3
2.1
88.33
91.00
%
—
9
26
11
39
2.94
2.39
1.1
1.1
—
—
—
0
0
19
92
2.20
2.38
1.7
1.4
—
—
—
0
0
8
23
3.60
2.30
1.5
2.5
3.57
3.98
g/l
—
8
23
9
29
3.22
2.26
2.7
2.2
16.60
16.00
u/ml
—
9
23
32
197
1.77
2.06
1.8
1.6
—
—
—
0
0
6
15
4.10
2.05
6.8
1.4
3.12
248.97
u/ml
—
6
15
142
1534
0.55
2.03
39.8
17.1
4.41
4.52
e12/l
1.24
137
1479
142
1533
0.55
2.00
41.2
17.1
39.01
40.25
%
1.51
136
1430
119
1339
0.63
1.95
5.1
4.5
6.03
5.98
mmol/l
0.21
107
1223
48
335
1.60
1.94
4.9
3.7
0.00
0.00
estimate
-0.00
24
93
142
1531
0.56
1.92
39.9
17.1
250.39
249.44
e9/l
0.06
137
1483
6
17
3.62
1.85
1.2
1.1
—
—
—
0
0
121
1056
1.51
1.61
7.6
3.8
15.43
14.72
pmol/l
2.03
116
956
5
15
3.40
1.53
1.4
1.3
—
—
—
0
0
0
41
0.00
1.33
0.0
1.3
—
—
—
0
0
5
18
2.83
1.29
1.0
1.3
—
—
—
0
0
38
283
1.44
1.12
2.0
1.8
555.38
435.61
pmol/l
0.72
29
231
8
41
2.00
1.10
1.9
1.4
8.95
3.25
ug/l
—
8
34
7
32
2.24
1.09
1.0
1.2
—
—
—
0
0
5
23
2.21
0.98
1.2
1.9
—
—
—
0
0
11
62
1.83
0.96
11.8
2.4
0.57
0.63
%
0.27
11
62
14
86
1.68
0.94
1.1
1.2
58.39
115.14
iu/ml
—
8
34
138
1461
0.71
0.93
16.2
8.4
26.96
24.43
u/l
1.10
129
1396
11
63
1.80
0.92
11.8
2.4
1.18
1.45
%
0.29
11
63
16
103
1.61
0.91
9.6
2.8
6.04
4.25
kpa
0.84
16
97
36
278
1.37
0.87
1.4
1.8
1.78
1.09
mg/l
0.46
21
217
0
25
0.00
0.79
0.0
1.2
—
—
—
0
0
0
27
0.00
0.78
0.0
1.7
—
—
—
0
0
9
53
1.74
0.77
1.0
1.2
—
—
—
0
0
117
1258
0.78
0.77
6.4
6.1
41.44
40.41
mmol/mol
0.45
106
1177
19
262
0.69
0.76
1.4
1.7
—
—
—
0
0
9
54
1.70
0.76
1.0
1.2
—
—
—
0
0
7
38
1.88
0.74
3.3
1.1
41.87
38.21
g/l
—
7
33
28
214
1.37
0.73
2.9
2.3
134.79
1.24
e6/l
0.47
12
109
19
135
1.46
0.73
2.1
1.6
—
—
—
0
0
70
610
1.25
0.70
4.1
2.6
170.93
105.85
ug/l
0.65
63
563
75
659
1.25
0.70
4.5
3.5
0.00
0.00
estimate
-0.00
26
107
7
42
1.69
0.69
3.3
1.1
11.50
10.82
g/l
—
7
37
19
137
1.44
0.68
1.9
1.5
—
—
—
0
0
7
44
1.62
0.66
3.3
1.1
3.21
3.80
g/l
—
7
39
7
44
1.62
0.66
3.3
1.1
6.83
7.75
g/l
—
7
39
7
44
1.62
0.66
3.3
1.1
2.59
3.05
g/l
—
7
39
7
44
1.62
0.66
3.3
1.1
—
—
—
0
0
8
49
1.66
0.63
1.4
1.6
—
—
—
0
0
17
230
0.71
0.62
1.5
1.3
2.40
11.84
u/ml
—
5
92
5
30
1.69
0.62
1.4
3.2
—
—
—
0
0
8
52
1.56
0.60
1.4
1.6
—
—
—
0
0
11
74
1.52
0.55
1.9
1.4
—
—
—
0
0
26
207
1.30
0.53
2.8
2.5
0.75
4.04
e6/l
—
8
102
74
666
1.20
0.51
5.6
4.8
0.00
0.00
estimate
-0.00
25
99
75
676
1.20
0.51
4.5
3.5
0.00
0.00
estimate
-0.00
24
95
79
865
0.84
0.51
3.3
3.2
—
—
—
0
0
38
321
1.24
0.49
3.8
2.3
349.90
9298.57
umol/l
2.03
30
274
32
266
1.25
0.48
2.2
1.8
1382.14
1104.57
nmol/l
0.59
21
206
8
57
1.42
0.43
1.1
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
4.3
—
19.40
—
0
5
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
7
105
0.65
0.40
1.7
1.6
—
—
—
0
0
19
230
0.80
0.34
1.5
1.3
14.29
33.24
iu/ml
—
7
76
6
88
0.67
0.34
1.0
1.0
—
—
—
0
0
10
132
0.74
0.33
1.9
2.6
3.88
7.63
ug/l
—
10
120
17
206
0.81
0.31
1.1
1.4
—
—
—
0
0
12
93
1.31
0.31
7.3
2.0
84.80
64.22
ml/min/173m2
—
5
37
12
149
0.79
0.27
1.8
2.2
—
—
—
0
0
35
390
0.87
0.26
3.3
2.9
5544.13
1213.80
ng/l
0.44
30
325
5
37
1.36
0.23
1.2
1.3
—
1.90
—
0
5
5
38
1.33
0.23
1.2
1.3
—
—
—
0
0
14
166
0.83
0.21
1.6
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
14
159
0.87
0.13
11.1
6.6
—
—
—
0
0
126
1284
0.93
0.12
7.9
4.7
1.62
1.88
mu/l
1.54
117
1170
55
526
1.07
0.11
5.1
3.6
—
—
—
0
0
5
44
1.14
0.10
1.4
1.8
—
—
—
0
0
8
76
1.06
0.07
1.4
1.4
—
—
—
0
0
10
91
1.11
0.04
1.0
1.3
—
—
—
0
0
91
898
1.03
0.03
3.3
3.0
71.25
42.38
u/l
1.92
84
835
38
371
1.03
0.02
1.6
1.7
1.42
1.30
mmol/l
0.48
28
316
52
529
0.98
0.02
4.5
3.7
31.36
102.18
ng/l
0.54
43
365
44
447
0.98
0.01
4.2
3.9
19.25
7.55
mg/mmol
0.50
29
293
58
573
1.02
0.01
2.0
1.9
92.59
93.60
pmol/l
0.07
37
282
31
304
1.02
0.00
8.1
3.6
24.32
24.74
%
0.05
13
142
33
326
1.02
0.00
1.1
1.4
0.87
1.10
u/ml
—
7
84
21
213
0.98
0.00
3.6
2.5
0.71
0.75
ug/l
0.08
14
143
34
343
0.99
0.00
1.9
1.5
17.53
20.57
nmol/l
0.78
29
297
127
1275
0.98
0.00
26.8
10.2
79.10
80.56
ml/min/173m2
0.24
113
997
136
1358
1.01
0.00
23.8
11.8
25.11
22.05
mg/l
0.55
123
1027
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
6
61
0.98
0.00
2.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
74.38
—
0
6
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1843.20
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_ENDOCRINE_NAS_WIDE – Malignant neoplasm of other endocrine glands and related structures, including Hilmo
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).